This is a summary of the European public assessment report (EPAR) for Insuman. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Insuman.
Therapeutic Indication
### Therapeutic indication Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
Therapeutic Area (MeSH)
ATC Code
A10AB01A10AC01
ATC Item
xa 10 ab 01 a 10 ac 01
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Insulin human | N/A | 人胰岛素 |
EMA Name
Insuman
Medicine Name
Insuman
Aliases
N/ANo risk management plan link.
